Erratum: B-cell-activating factor receptor expression on naïve and memory B cells: Relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy (Annals of the Rheumatic Diseases (2010) 69, (2181-2188) DOI:10.1136/ard.2010.131326);B-cell-activating factor receptor expression on naive and memory B cells: Relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2181-2188

  De La Torre, Inmaculada ^a,b   Moura, Rita A ^c   Leandro, Maria J ^a   Edwards, Jonathan ^a   Cambridge, Geraldine ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Instituto de Biologia Molecular   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; C REACTIVE PROTEIN; CD27 ANTIGEN; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RELAPSE; RHEUMATOID ARTHRITIS;

EID: 77956900662     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.131326corr1     Document Type: Erratum

References (40)

1. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710. (Pubitemid 30002351)
2. Shulga-Morskaya S, Dobles M, Walsh ME, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-41.
3. Castro I, Wright JA, Damdinsuren B, et al. B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2. J Immunol 2009;182:7729-37.
4. Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. J Immunol 2007;179:3872-80.
5. Sasaki Y, Casola S, Kutok JL, et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004;173:2245-52.
6. Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA 2009;106:13945-50.
7. Darce JR, Arendt BK, Wu X, et al. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-86.
8. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9:491-502.
9. Candon S, Gottenberg JE, Bengoufa D, et al. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis 2009;68:1208-12.
10. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86.
11. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-19.
12. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-16.
13. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-6. (Pubitemid 44661743)
14. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-9.
15. Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009;114:5362-7.
16. Gottenberg JE, Miceli-Richard C, Ducot B, et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009;11:R114.
17. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32.
18. Leandro MJ, de la Torre I. Translational Mini-Review Series on B Cell-Directed Therapies: the pathogenic role of B cells in autoantibody- associated autoimmune diseases - lessons from B cell-depletion therapy. Clin Exp Immunol 2009;157:191-7.
19. Sellam J, Miceli-Richard C, Gottenberg JE, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-7.
20. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
21. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75.
24. Thurlings RM, Vos K, Gerlag DM, et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657-64.
25. Carter RH, Zhao H, Liu X, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005;52:3943-54.
26. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86.
27. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65(Suppl 3):iii34-6.
28. Darce JR, Arendt BK, Chang SK, et al. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J Immunol 2007;179:7276-86.
29. Arechiga AF, Habib T, He Y, et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009;182:3343-7.
30. Kubo T, Uchida Y, Watanabe Y, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 2009;206:1971-82.
31. Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-67.
32. Rudnicka W, Burakowski T, Warnawin E, et al. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients. Eur J Immunol 2009;39:1211-20.
33. Honczarenko M, Glodek AM, Swierkowski M, et al. Developmental stage-specific shift in responsiveness to chemokines during human B-cell development. Exp Hematol 2006;34:1093-100.
34. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991;173:487-9.
35. Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68:1011-16.
36. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11:R131.
37. Möller B, Aeberli D, Eggli S, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009;11:R62.
38. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178:6624-33.
39. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008;58:1762-73.
40. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004;197:179-91.